This article is more than 5 years old. Information may no longer be current.
Taxane-induced peripheral neuropathy not related to OS, DFS or RFS
Click Here to Manage Email Alerts
There was no significant relationship between peripheral neuropathy and clinical outcomes among patients with breast cancer who received adjuvant chemotherapy that included a taxane, according to a study.
Bryan P. Schneider, MD, associate professor in the department of medicine, division of hematology/oncology at Indiana University, presented data from an analysis of the E1199 trial. This trial included 5,052 patients who received adjuvant doxorubicin and cyclophosphamide, followed by paclitaxel every 3 weeks for four cycles; weekly paclitaxel for 12 weeks; docetaxel every 3 weeks for four cycles; or weekly docetaxel for 12 weeks.
In this analysis, researchers examined whether there was a relationship between peripheral neuropathy and clinical outcomes in the E1199 trial. They conducted a landmark analysis and a time-varying analysis and measured the relationship between peripheral neuropathy and DFS, relapse-free survival (RFS) and OS.
In the landmark analysis, there was no significant difference in OS, DFS and RFS between patients who experienced peripheral neuropathy and patients who did not. This remained true among patients who had ER-positive, HER-2–positive or triple-negative subtypes. In the time-varying analysis, there was also no significant difference in OS, DFS and RFS between patients who experienced peripheral neuropathy and patients who did not.
“We did observe a trend for increased risk of peripheral neuropathy in patients who were obese and black patients,” Schneider said. “There was also a trend for decreased risk of peripheral neuropathy in patients who were premenopausal. There was a significant association between peripheral neuropathy and patients with grade 2 to grade 4 treatment-associated hyperglycemia.”
Schneider also said there was significantly more peripheral neuropathy in patients who received weekly paclitaxel compared with patients who received paclitaxel every 3 weeks for four cycles. There was less peripheral neuropathy in patients who were in either regimen of docetaxel.
For more information:
- Schneider B. #270.
Disclosure: Dr. Schneider reports no relevant financial disclosures.